Stromal Cells Present in the Melanoma Niche Affect Tumor Invasiveness and Its Resistance to Therapy.
adipocytes
cancer-associated fibroblasts
drug resistance
invasion
keratynocytes
melanoma
tumor microenvironment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Jan 2021
07 Jan 2021
Historique:
received:
11
12
2020
revised:
29
12
2020
accepted:
05
01
2021
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
31
3
2021
Statut:
epublish
Résumé
Malignant melanoma is a highly metastatic type of cancer, which arises frequently from transformed pigment cells and melanocytes as a result of long-term UV radiation exposure. In recent years, the incidence of newly diagnosed melanoma patients reached 5% of all cancer cases. Despite the development of novel targeted therapies directed against melanoma-specific markers, patients' response to treatment is often weak or short-term due to a rapid acquisition of drug resistance. Among the factors affecting therapy effectiveness, elements of the tumor microenvironment play a major role. Melanoma niche encompasses adjacent cells, such as keratinocytes, cancer-associated fibroblasts (CAFs), adipocytes, and immune cells, as well as components of the extracellular matrix and tumor-specific physicochemical properties. In this review, we summarize the current knowledge concerning the influence of cancer-associated cells (keratinocytes, CAFs, adipocytes) on the process of melanomagenesis, tumor progression, invasiveness, and the emergence of drug resistance in melanoma. We also address how melanoma can alter the differentiation and activation status of cells present in the tumor microenvironment. Understanding these complex interactions between malignant and cancer-associated cells could improve the development of effective antitumor therapeutic strategies.
Identifiants
pubmed: 33430277
pii: ijms22020529
doi: 10.3390/ijms22020529
pmc: PMC7825728
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Centre, Poland
ID : OPUS 15, No. 2018/29/B/NZ5/00967
Références
Exp Dermatol. 2020 Apr;29(4):436-445
pubmed: 31957066
Br J Cancer. 2017 Aug 8;117(4):535-544
pubmed: 28697174
PLoS One. 2012;7(1):e30750
pubmed: 22295108
Int J Mol Sci. 2019 Dec 31;21(1):
pubmed: 31906113
Crit Rev Oncol Hematol. 2004 Mar;49(3):269-75
pubmed: 15036266
Pigment Cell Melanoma Res. 2018 Mar;31(2):297-307
pubmed: 29045061
Melanoma Res. 2016 Jun;26(3):236-44
pubmed: 26825037
Cells. 2019 Jun 04;8(6):
pubmed: 31167491
Cell Signal. 2019 Nov;63:109386
pubmed: 31394192
Int J Cancer. 2020 Feb 15;146(4):895-905
pubmed: 30734283
Oncotarget. 2016 Mar 29;7(13):16396-408
pubmed: 26918939
Cancer Microenviron. 2012 Apr;5(1):73-82
pubmed: 21892698
J Am Acad Dermatol. 2000 Oct;43(4):703-4
pubmed: 11004633
Genes Dev. 1999 Apr 15;13(8):1015-24
pubmed: 10215628
Cancer Biol Ther. 2012 Feb 1;13(3):123-9
pubmed: 22236832
J Neurooncol. 2014 May;117(3):485-91
pubmed: 24504498
J Exp Clin Cancer Res. 2011 Feb 21;30:21
pubmed: 21338489
Int J Cancer. 2015 Jan 15;136(2):258-70
pubmed: 24844408
EMBO Mol Med. 2017 Aug;9(8):1011-1029
pubmed: 28606996
J Biol Chem. 2015 Oct 2;290(40):24267-77
pubmed: 26269601
Int J Cancer. 2019 Oct 1;145(7):1946-1957
pubmed: 30873585
Cancer Metab. 2016 Dec 7;4:21
pubmed: 27980732
Am J Pathol. 2000 May;156(5):1515-25
pubmed: 10793063
J Invest Dermatol. 2005 Aug;125(2):307-11
pubmed: 16098041
Mol Oncol. 2015 Mar;9(3):689-703
pubmed: 25499031
Cancer Res. 2002 Dec 15;62(24):7328-34
pubmed: 12499276
Cancer Res. 1987 Jun 15;47(12):3057-61
pubmed: 3034401
Biochim Biophys Acta. 2013 Oct;1831(10):1533-41
pubmed: 23500888
J Biol Chem. 2003 Apr 4;278(14):11888-96
pubmed: 12529376
Nature. 2012 Jul 26;487(7408):500-4
pubmed: 22763439
Signal Transduct Target Ther. 2019 Dec 24;4:63
pubmed: 31885878
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158314
J Cell Sci. 2000 May;113 ( Pt 9):1535-42
pubmed: 10751145
Oncotarget. 2016 Feb 9;7(6):7179-92
pubmed: 26769849
Int J Cancer. 2012 Feb 1;130(3):497-508
pubmed: 21387314
Curr Med Chem. 2014 Apr;21(10):1255-67
pubmed: 24304284
J Mol Recognit. 2017 Nov;30(11):
pubmed: 28612997
Tumour Biol. 2016 Oct;37(10):14235-14248
pubmed: 27571738
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Science. 2009 Aug 28;325(5944):1134-8
pubmed: 19713527
Mol Endocrinol. 2009 Jun;23(6):925-31
pubmed: 19324969
Differentiation. 2002 Dec;70(9-10):522-36
pubmed: 12492494
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
Br J Dermatol. 2016 Dec;175(6):1210-1220
pubmed: 27167239
Cancers (Basel). 2015 Dec 11;7(4):2443-58
pubmed: 26690480
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
Sci Signal. 2019 Jul 23;12(591):
pubmed: 31337739
Int J Biochem Cell Biol. 2008;40(5):874-91
pubmed: 18280770
Cancer Discov. 2014 Jul;4(7):816-27
pubmed: 24771846
Nature. 2016 Apr 14;532(7598):250-4
pubmed: 27042933
Integr Biol (Camb). 2014 Dec;6(12):1211-7
pubmed: 25363644
Genes Dev. 2016 May 1;30(9):1002-19
pubmed: 27151975
RNA Biol. 2015;12(8):810-23
pubmed: 26176991
Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9215-9
pubmed: 1409627
J Cell Physiol. 2019 Aug;234(10):18249-18261
pubmed: 30851074
Histochem Cell Biol. 2012 Oct;138(4):653-67
pubmed: 22688676
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013762
Horm Mol Biol Clin Investig. 2015 Jan;21(1):57-74
pubmed: 25781552
J Biol Chem. 2014 Oct 31;289(44):30525-37
pubmed: 25228694
Oncogene. 2004 Nov 4;23(52):8509-19
pubmed: 15378016
Physiol Res. 2018 Jun 27;67(Suppl 1):S257-S264
pubmed: 29947545
Cancer Res. 2001 May 1;61(9):3819-25
pubmed: 11325858
Oncotarget. 2013 Nov;4(11):1986-98
pubmed: 24161908
Oncogene. 1991 Jul;6(7):1115-24
pubmed: 1861861
Oncotarget. 2014 Oct 30;5(20):10127-39
pubmed: 25333256
Cancer Discov. 2018 Aug;8(8):1006-1025
pubmed: 29903879
J Invest Dermatol. 1993 Mar;100(3):259S-268S
pubmed: 8440900
PLoS One. 2012;7(7):e40378
pubmed: 22911700
J Invest Dermatol. 2020 Nov;140(11):2268-2279.e11
pubmed: 32275977
Mol Cell. 2015 Aug 20;59(4):664-76
pubmed: 26236014
Oncotarget. 2016 May 3;7(18):26653-69
pubmed: 27049717
Cancer Res. 1994 Jun 15;54(12):3242-7
pubmed: 8205546
Exp Dermatol. 2000 Feb;9(1):34-41
pubmed: 10688373
Cell Cycle. 2008 Jul 15;7(14):2257-67
pubmed: 18635971
Dev Cell. 2019 May 6;49(3):306-307
pubmed: 31063747
Cancer Biol Ther. 2009 Oct;8(19):1871-9
pubmed: 19713740
Pigment Cell Melanoma Res. 2012 Mar;25(2):219-30
pubmed: 22136309
Cancer Res. 2016 Jul 15;76(14):4051-7
pubmed: 27216185
J Biol Chem. 2014 Mar 21;289(12):8442-9
pubmed: 24492617
Expert Opin Drug Discov. 2016 Sep;11(9):907-16
pubmed: 27327499
Int J Dev Biol. 2005;49(2-3):173-80
pubmed: 15906230
Cancer Discov. 2013 Dec;3(12):1378-93
pubmed: 24104062
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32817394
Rom J Morphol Embryol. 2018;59(1):23-28
pubmed: 29940608
Cancer Res. 2014 Aug 1;74(15):4122-32
pubmed: 25035390
Cell Cycle. 2006 Aug;5(15):1597-601
pubmed: 16880743
Eur J Cancer. 2013 Feb;49(3):642-57
pubmed: 23200191
Front Oncol. 2019 Apr 17;9:268
pubmed: 31058079
J Biomed Res. 2011 Mar;25(2):135-40
pubmed: 23554681
Sci Signal. 2012 Jan 10;5(206):ra3
pubmed: 22234612
Cancers (Basel). 2020 Jun 15;12(6):
pubmed: 32549336
Int J Mol Sci. 2020 Mar 30;21(7):
pubmed: 32235439
Sci Rep. 2019 Sep 6;9(1):12861
pubmed: 31492946
BMB Rep. 2018 Oct;51(10):486-492
pubmed: 30158025
Nat Cell Biol. 2016 Sep;18(9):1006-17
pubmed: 27548915
J Investig Dermatol Symp Proc. 1996 Apr;1(2):188-94
pubmed: 9627715
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
Exp Cell Res. 2003 Mar 10;284(1):14-30
pubmed: 12648463
Cancers (Basel). 2020 Jul 29;12(8):
pubmed: 32751207
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Cancers (Basel). 2019 Aug 28;11(9):
pubmed: 31466300
Oncogene. 2019 Dec;38(50):7491-7503
pubmed: 31435021
Annu Rev Pharmacol Toxicol. 2002;42:283-323
pubmed: 11807174
Int J Mol Sci. 2016 Jun 02;17(6):
pubmed: 27271600
J Exp Clin Cancer Res. 2018 Oct 3;37(1):242
pubmed: 30285793
Tissue Barriers. 2014 Jul 22;2:e29528
pubmed: 25068098
J Cell Commun Signal. 2011 Aug;5(3):219-26
pubmed: 21667293
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5930-E5939
pubmed: 28684402
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
J Clin Invest. 2013 May;123(5):2155-68
pubmed: 23543055
J Cancer Res Clin Oncol. 2019 Sep;145(9):2241-2250
pubmed: 31342168
Science. 2010 Nov 5;330(6005):827-30
pubmed: 21051638
J Invest Dermatol. 1996 Sep;107(3):404-11
pubmed: 8751978
Oncol Rep. 2010 Apr;23(4):901-7
pubmed: 20204272
Sci Rep. 2018 Aug 27;8(1):12905
pubmed: 30150674
Nat Rev Endocrinol. 2016 Aug;12(8):436
pubmed: 27282447
FASEB J. 2002 Feb;16(2):219-21
pubmed: 11744618
J Cancer. 2015 Jun 23;6(8):717-26
pubmed: 26185533
Cancer Res. 2003 Oct 15;63(20):6751-7
pubmed: 14583470
Cell Death Dis. 2019 Jul 22;10(8):562
pubmed: 31332163
Mol Med Rep. 2017 Aug;16(2):2254-2258
pubmed: 28627656
Nature. 2017 Jan 5;541(7635):41-45
pubmed: 27974793
Pigment Cell Melanoma Res. 2017 May;30(3):294-306
pubmed: 28222242
Sci Rep. 2020 Feb 7;10(1):2149
pubmed: 32034251
J Invest Dermatol. 2015 Nov;135(11):2805-2813
pubmed: 26168233
Pigment Cell Melanoma Res. 2011 Apr;24(2):382-5
pubmed: 21091638
Nature. 2008 Jun 5;453(7196):783-7
pubmed: 18454136
Arch Biochem Biophys. 2012 Aug 1;524(1):43-7
pubmed: 22085498
Photochem Photobiol. 1996 Apr;63(4):397-400
pubmed: 8934748
Mol Cancer. 2015 Jan 05;14:1
pubmed: 25560632
Am J Pathol. 1994 Oct;145(4):837-45
pubmed: 7943174
Matrix Biol. 2018 Dec;74:52-61
pubmed: 29885461
J Cell Commun Signal. 2016 Sep;10(3):191-196
pubmed: 27553358
Int J Mol Sci. 2020 Nov 07;21(21):
pubmed: 33171792
EMBO J. 2020 Feb 3;39(3):e102525
pubmed: 31919869
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Melanoma Res. 2012 Apr;22(2):114-22
pubmed: 22395415
Curr Oncol Rep. 2008 Sep;10(5):439-46
pubmed: 18706274
Cancer Biol Ther. 2006 Dec;5(12):1640-6
pubmed: 17106243
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188456
pubmed: 33153973
Angiogenesis. 2012 Sep;15(3):481-95
pubmed: 22614697
Mol Cancer. 2010 Jul 28;9:201
pubmed: 20667128
Tumour Biol. 2018 Feb;40(2):1010428318756203
pubmed: 29421992
PLoS One. 2013 Apr 16;8(4):e61524
pubmed: 23613870
Mol Biol Rep. 2020 Mar;47(3):2137-2147
pubmed: 32080807
Cancer Biol Ther. 2019;20(11):1366-1379
pubmed: 31366280
Int J Cancer. 2011 Oct 1;129(7):1730-40
pubmed: 21128237
Genes Cells. 1999 Jun;4(6):353-62
pubmed: 10421844
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
J Cell Biochem. 2016 Jul;117(7):1697-706
pubmed: 26666522
Lab Invest. 1987 May;56(5):461-74
pubmed: 3553733
Oncogene. 2001 Aug 2;20(34):4676-84
pubmed: 11498790
Melanoma Res. 2006 Jun;16(3):207-11
pubmed: 16718267
Lancet Oncol. 2002 Jan;3(1):35-43
pubmed: 11905603
Clin Cancer Res. 2019 Nov 15;25(22):6852-6867
pubmed: 31375515
Curr Pharm Biotechnol. 2011 Dec;12(12):2165-75
pubmed: 21619542
Pigment Cell Melanoma Res. 2020 Mar;33(2):293-304
pubmed: 31505093
Arch Dermatol Res. 2003 Nov;295(6):236-41
pubmed: 14530987
Life Sci. 2015 Oct 15;139:16-23
pubmed: 26297445
Cancer Lett. 2016 Jul 1;376(2):318-27
pubmed: 27063098
J Transl Med. 2016 Feb 24;14:56
pubmed: 26912358
Expert Opin Investig Drugs. 2019 Nov;28(11):977-988
pubmed: 31594388
Cancer Biol Med. 2016 Mar;13(1):101-19
pubmed: 27144066
Matrix Biol. 2018 Aug;68-69:44-66
pubmed: 29574063
Cancer Res. 2005 May 15;65(10):4292-9
pubmed: 15899821
Clin Cancer Drugs. 2015;2(2):138-147
pubmed: 27054085
Exp Mol Pathol. 2009 Dec;87(3):189-94
pubmed: 19747910
Int J Obes (Lond). 2018 Mar;42(3):344-352
pubmed: 28883539